Applicants St. Title Cont. of Mailing by Express Mail CT CFR 1 St. Express Mail Latest No. Cont. of Mailing by Express Mail CT CFR 1 St. Express Mail Latest No. Person Application Date 17 CFR 1 St.) Proceedings No. 18 Cont. of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express Mail CT CFR 1 St.) Procedure of Mailing by Express	Section 1 Sectio
\$252 ¥85	

RECEIVED

JAN 2 7 3004

PAUSSAU 0000

Atty. Docket No.:

20200/20931)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Kreutzer, et al.

Serial No.:

10/612,179 July 2, 2003

Filed: Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

droup Art Unit .

Conf. No.:

.: 323

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.88

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Cournissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

ge of Person Maijing Pape

Signature of Person Mailing Pages

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- Information Disclosure Statement;
- Form PTO-1449;
- Copies of Cited References; and
- Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 20200/2093D. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted.

Date: January

January M. 2004

Name: Barbara A Gyure Registration No.: 34,614 Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Teb 617-239-0100

Atty. Docket No.:

20200/2093D

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kreutzer, et al.

Serial No.: Filed:

10/612,179

July 2, 2003

Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

Conf. No.:

1645

5239

CERTIFICATE OF MAILING UNDER 37 C.F.R. \$ 1.80

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450,

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Information Disclosure Statement;
- Form PTO-1449; 2.
- 3. Copies of Cited References; and
- Ž. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 20200/2093D. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted.

Date: January 8, 2004

Name: Barbara A.Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket No.:

20200/2093D

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Kreutzer, et al.

Serial No.:

10/612,179 July 2, 2003

Filed: Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

5239

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

> Brenda M. Woods Varga of Person Mailipg Paper

Signature of Person Marling Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98</u>

Dear Sin:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of a portion of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 09/889,802. Copies of the documents in the list which were not submitted with the parent application are enclosed for the Examiner's convenience. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: January 8, 2004

Respectfully submitted,

Name: Barbara A. Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

USPTO Form 1489 U.S. Department of Community Patrick and Tradentiath Office INFORMATION DISCLOSURE STATEMENT			Anomey Docket No. 20200/2093D		Scrial No. 10/612,179		
				Applicani(s): Kreutze	retal.		
on the state of th				Piling Date: July 2, 2003			Group: 1645
U.S. PAT	TENT D	<u>OCUMENTS</u>	***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	••••		
Examiner Initial		Patent No.	Date	Name	Class	Subviass	Filing Date (if appropriate)
***************************************	<u> </u>	2003/0198627 A1	Oct. 23, 2003	Arts, et al.	424	93.21	Aug. 23, 2002
******	2	2003/0190635 A1	Oct. 9, 2003	McSwiggen	435	6	Jul. 25, 2002
***************************************	3.	2003/0180756 A1	Sep. 25, 2003	Shi, et al.	435	6	Nov. 21, 2002
	4.	2003/0176671 A1	Sep. 18, 2003	Reed, et al.	536	23.1	Feb. 7, 2002
•	5	2003/0157036 A1	Aug. 21, 2003	Davis, et al.	424	46	Nov. 4, 2002
	6.	2003/0148341 A1	Aug. 7, 2003	Sin, et al.	435	6	Nov. 5, 2002
	7.	2003/0143732 A1	Jul. 31, 2003	Fosnaugh, et al.	435	325	Aug. 20, 2002
•••••	8.	2003/0125281 A1	Jul. 3, 2003	Lewis, et al.	\$14	44	May 28, 2002
	9	2003/0108923 A1	Jun. 12, 2003	Tuschi, et al.	435	6	Sep. 26, 2002
***************************************	10.	2002/0086356 A1	Jul. 4, 2002	Tuschl, et al.	435	69.1	Mar. 30, 2001
*************	11.	6,423,489 B1	Jul. 23, 2002	Anderson, et al.	435	б	May 30, 1995
***************************************	12	6,346,398	Feb. 12, 2002	Pavco, et al.			
	13.	6,355,415	Mar. 12, 2002	Wagner, et al.			
*******************	14.	6,482,803	Nov. 19, 2002	Ruih, et al.	*****************		
	15.	6,183,959	Feb. 6, 2001	Thompson	***************************************		
	16.	6,225,291	May 1, 2001	Lewin, et al.			
***	17.	6,245,560	June 12, 2001	Lisziewicz			
•••••	18.	6,245,748	June 12, 2001	Wellstein, et al.			
	19.	6,255,071	July 3, 2001	Beach, et al.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	20	6,057,156	May 2, 2000	Alditar , et al.			
	21,	6,071,890	June 6, 2000	Scheule, et al.			
······	22,	6,077,705	June 20, 2000	Disane, et al.			
	23	6,080,851	June 27, 2000	Pachuk, et al.			
	24,	.6,087,164	July 11, 2000	Hochberg, et al.		***************************************	
······································	25.	6,087,172	July 11, 2000	Veerapaneni, et al.			
	26.	6,099,823	Aug. 8, 2000	Falb			***************************************

		p* 4 2000 00 00 00						***************************************
	27.	6,100,087	Aug. 8, 2000	Rossi, et al.				***
	28.	6,100,444	Aug. 8, 2000	Frelinger, et al.				
	29.	6,107,094	Aug. 22, 2000	Crooke				
	30.	5,968,737	Nov. 16, 1999	Ali-Osman , et al.				****************
	31	5,985,620	Nov. 16, 1999	Sioud				***************************************
	32.	5,908,779	June 1, 1999	Carmichael, et al.				****************
	33.	5,898,031	Apr 27, 1999	Crooke	(185) (65 bir			
	34.	.5,891,717	Apr. 6, 1999	Newgard , et al.	****		***************************************	
	35	5,866,701	Feb. 2, 1999	Hampei, et al.		***************************************		******
	36.	5,864,028	Jan. 26, 1999	Sioud			***************************************	referencement of a second second second
	37.	5,854,067	Dec. 29, 1998	Newgard , et al.		***************************************		***************************************
	38.	5,814,500	Nov. 1998	Dietz		***************************************		
	39	5,811,300	Nov. 22, 1998	Sülliyan , et al.			3	
	40.	5,811,275	Noy. 22, 1998	Wong-Staul , et al.		***************************************	***************************************	************
	41.	5,837,510	Nov. 17, 1998	Goldsmith, et al.				***************************************
	42.	5,824,519	Oct. 20, 1998	Norris, et al				*****
	43.	5,712,257	Jan. 1998	Carter		-		***********
	44,	5,639,655	June 17, 1997	Thompson, et al.				***************************************
	45.	5,635,385	June 3, 1997	Leopoid, et al.	·			*********
	46.	5,616,459	Apr. 1, 1997	Kramer, et al.	-	•	***************************************	
	47,	5,574,142	Nov. 12, 1996	Meyer, Jr., et al.			***************************************	**************
	48.	5,525,468	June 11, 1996	McSwiggen	***************************************			***********
	49.	5,496,698	Mar. 5, 1996	Draper, et al.	***************************************		······································	************
	.50.	5,246,921	Sep. 21, 1993	Reddy, et al	-		***************************************	iii in
	51.	5,225,347	July 6, 1993	Goldberg, et al.			***************************************	••••
***************************************	52.	5,112,734	May 12, 1992	Kramer, et al.				***************************************
POREIG	N PATE	NT DOCUMENTS			······			******
Examiner Initial		Document No.	Publication	Country	Chairs	Swinclass	Yransia	tion
***************************************			Date				YES	NO
	53.	DE 101 00 586 CT	April 11, 2002	Deutschland (Germany)	Cl2N	15/11		Х
		,		1	3	}	**********	
	\$4.	WO 03/080807 A2	Oct. 2, 2003	PCT	CIZN		X	

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	2.	23263 252 252 4 52 4 5 25	to the second	A. Sausa				
***************************************	56.	WO 03/074684 A2	***************************************	PCT	CIZN		<u>X</u>	
	57.	WO 03/070972 A2	· · · · · · · · · · · · · · · · · · ·	PCT	C12	·	X	
	58	WO 03/070969 A2	Aug. 28, 2003	PCT			X	
	59,	WO 03/070750 A2	Aug. 28, 2003	PCI	<u>C07K</u>		X	
	60	WO 03/070283 A2	Aug. 28, 2003	PCT	AGIK	48/00	X	
	61.	WO 03/016572 A1	Feb. 27, 2003	FCI	C12Q	1/68	X	
	62.	WO 03/012052 A2	Feb. 13, 2003	PCT	CI2N		X	
	63	WO 02/068637 A2	Sep. 6, 2002	PCT	CIZN	15/11	X	***************************************
	64.	WO 02/068635 A2	Sep. 6, 2002	PCT	CI2N	13/11	Х	
	65,	WO 02/44321 A2	Jun. 6, 2002	PCT	CI2N		X	***************************************
<u></u>	66.	WO 02/26780 A2	Apr. 4, 2002	PCT	C07K	14/00	X	
	67.	WO 01/75164 A2	Oct. 11, 2001	PCT	C12Q	1/68	Х	
	68.	WO 00/68374	Nov. 16, 2000	PCT	CI2N	15/11	X	
	69.	WO 00/63364	Oct. 26, 2000	PCT				
	70.	WO 00/44895	Aug. 3, 2000	PCT	Cl2N	15/11		χ
	71.	WO 00/44914	Aug. 3, 2000	PCT			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	72.	WO 00/01846	Jan. 13, 2000	PCT			***************************************	
	73.	WO 99/61631	Dec. 2, 1999	PCT				
	74.	WO99/53050	Oct. 21, 1999	PCT				
	75.	WO 99/49029	Sept. 30, 1999	PCI			***************************************	
	76.	WO 99 32619	July 1, 1999	PCT			************	************
	77.	WO 99/15682	Apr. 1, 1999	PCT			***	
	78.	WO 98/53083	Nov. 26, 1998	PCI				
	79.	DE 196 31 919 C2	July 1998	DE			X	
	80.	DE 196 18 797 C2	Nov. 13, 1997	DE			***************************************	X
	81.	DE 196 18 797 A1	Oct. 1996	DE			X	
	82.	WO94/01550	Jan. 20, 1994	PCT				
OTHER I	XXCUM	ENTS (including Auth	***************************************	A COLUMN TO THE PROPERTY OF TH			***************************************	
	83.			khtar, Saghir, Publishe	r CRC	***************************************		***************
	84.			Science, 293:811-813	************	*********************	*****	***************************************
	85.	Asanuma, il. et al. (999), "Photoregula	tion der Bildung und I leinheit", Angew. Cher	Dissoziation	cines DN:	A-Duplexe	s durch
	86.	Ausubel, F. et al. (19						

	87.	Azhayeva, E. et al., (1997), "Inhibitory properties of double helix forming circular oligomicleotides"; Nucl. Acids Res., 25:4934-4961.
	88.	Bahramian et al.; MOLECULAR AND CELLULAR BIOLOGY, Vol. 19:274 - 283, "Transcriptional and Posttranscriptional Silencing of Rodent at (I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999
	89.	Barwkar, D.A. et al.; Proc. Natl. Acad. Sci USA, Vol. 95:11047 – 11052, September 1998, Chemistry, Biochemistry
	90,	Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.
	91.	Bhan et al., Nucleic Acid Research, 1997; Vol. 25; p. 3310
	92,	Billy, et al. (2001) PNAS 98(25):14428-33
	93.	Borecky et al. (1981-82) Tex Rep Biol Med 41:575-81 Abstract Only
	94.	Custelli, J. et al., (998), "The 2-5A system in viral infection and apoptosis", Biomed. Pharmacother., 52:386-390.
	95.	Cobalada, C. et al., (2000), "In vivo inhibition by a site-specific entalytic RNA subunit of Rhase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", <i>Blood</i> , 95(3):731-737.
	96.	Datenbank MEDLINE bei STN: AN 1999091059 MEDLINE; DN 99091059 zu: Use of dsRNA- mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Kennerdell J.R.; Carthew R.W.; CELL, (1998 Dec. 23) 95(7):1017-1026.
	97.	Downward, I. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21" , Proc. Natl. Acad. Sci. USA", 87:5998-6002.
	98.	Elbashir, et al. (2001) Nature 411:494-498
	99.	Fire, 9/99, RNA-triggered gene stlencing, Trends Genet, 15: 358-363.
	100.	Fire, A., et al., 1991, Production of Antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle, Development 113; 503-514
	101.	Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins", <i>Journal of the National Cancer Institute</i> , 93(6):463-471.
	102.	Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", <i>Proc. Neal. Acad. Sci. USA</i> ", 85:5026-5030.
	103.	Grasby, JA et al.; Biochemistry 1995 Mar 28; 34(12):4068 - 76
***************************************	104.	Griffey, RH et al.: J Med Chem 1996 Dec 20; 39(26):5100-9
*****	105.	Ha, Let al.; Genes Dev 1996 Dec 1;10(23);3041-50
	106.	Hamilton et al.; SCIENCE, Vol. 286:950 - 951, "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants (Oct. 29, 1999)
	107.	Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", <i>Nature</i> , 404:293-296.
	108.	Hoke, GD et al.; Nucleic Acids Res 1991 Oct 25; 19(20):5743-8

133.	Nikiforov, et al. (1992) Nucleic Acids Research 20(6):1209-1214
132.	Ngo, H., et al., 1998, Double-stranded RNA induces mRNA degradation in Trypanosoma brucei, Proc Natl. Acad. Sci. 95: 14687-14692.
131.	
130	Misquitta, L. and Paterson, B.M., 1999, Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle formation, Proc. Natl. Acad. Sci. 96: 1451-1456
129	Montgomery, et al., July 1998, Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression, TIG, Vol. 14, No. 7., pgs. 255-258
128	interference in Caenorhabditis elegan, Proc. Natl. Acad. Sci. 95: 15502-15507.
127	conserved and divergent aspects of mesodermal patterning, Genes and Development, 12: 2623-2635.
126	3 20072-01 2003333 (1979), 274, (20710180-1018)
125	12000000, 3771, 101, 31, 201, 203
124	330 0000 1230 001 20121274
123	1281, 372 1 22
122	The state of the s
121	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
120	dsRNAs that Are Degraded to Generate New siRNAs", Cell, 107:297-307.
115	100 100 100 100 100 100 100 100 11, 1999
133	22 10-100 2007 1777, 9. 200 1878 1871 2970
: 7.5	Controls Developmental Timing in C. elegans and is Regulated by the lin-4 RNA
173	2000 2000 2000 2000 2000 2000 2000 200
11.	Structure 7(11): 1345-1352
114	Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Dec 23, 1998
11	modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349
3.5	37.37.37.37.37.37.37.37.37.37.37.37.37.3
	055 AV 75 CAST 10000 7, DOWN 7442
	7777 - 707 27 107 27 107 27 107 27
10	Gigger Tissue Factor", Nucleic Acids Research, 30(8):1757-1766.

134.	Pegmm, MD et al.: J. Clin Oncol 1998 Aug.: 16(8):2659 - 71
135.	Ravinderjit, et al. (1997) Bioconjugate Chem. 8:376-377
136.	Rosalind C. Lee, et al.; CELL, Vol. 75, 843 – 854, March 12, 1993; "The C. elegans Herochronic Gene- lin-4 Encodes Small RNAs with Antisense Complementary to lin-14"
137.	Seydoux, G., et al., 1996, Repression of gang expression in the embryonic germ lineage of C. cleyans. Nature 382: 713-716
138.	Sharp, P.A., (2001), "RNA interference - 2001", Genes & Development, 15:485-490.
138.	Sharp, P.A., 1999, RNAi and double-stranded RNA. Gene and Development 13: 139-141
140.	Sijen, T. et al., (2001), "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, 107:465-476.
141,	Strauss; SCIENCE, Vol. 286:886; "Candidate 'Gene Silencers' Found" Oct. 29, 1999
142.	James D. Thompson, 12/99, Shortcuts from gene sequence to function, Nature Biotechnology, vol. 17, pp. 1158-1159
143.	Timmons et al.; NATURE, 395(6705:854); "Specific Interference by Ingested daRNA" Oct 29, 1998
144.	Tuschi et al. (Dec 1999) Genes and Dev. 13:3191-7
145.	Voinnet, O. and Baulcombe, D. C., Nature (1997), 398:553
146.	Wagner, et al., 2/19/98, Double-stranded RNA poses puzzle, Naiwe, 391: 744-745
147.	Wargsiius, et al., 1999, Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem Biophys Res Com., 263: 156-161.
148.	Waterhouse et al.: PNAS, Vol. 95:13959 - 13964, "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"November, 1998
149.	Wisney, et al. (2000) Nature Cell Biology 2:70-75
150.	Wild, K. et al., (1999), "The 2 Å structure of helix 6 of the human signal recognition particle RNA", Structure, 7(11):1345-1352.
151.	Yang, D. et al., (2000), "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in <i>Drosophila</i> embryos", <i>Current Biology</i> , 10:1191-1200.
152.	Yang Shi, et al.; GENES & DEVELOPMENT, Vol. 12, (No. 7):943 – 955; "A CBP/p300 homolog specifies multiple differentiation pathways in Caenorhabditis elegans" Apr 1, 1998
153.	Zamore, et al. (2000) Cell 101:25-33
154	International Search Report of International Application No. PCT/EP02/00151.
EXAMINER	DATE CONSIDERED

*IXAMINES: Initial direference considered, whether or not educate is in confirmance with MPHF 8/9. Draw like through station if not is confirmance and an emotional include capy of this layer with and constantiation in Applican.

^{**}Copies of references and secreted in the case of this submission.